SEC Form 4 · accession 0001237899-15-000026

REGENERON PHARMACEUTICALS, INC. · REGN

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Michael S Aberman

Officer — SVP Strategy Investor Relation

Period of report

Mar 17, 2015

Accepted (ET)

Mar 19, 2015 · 4:05 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000872589

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Mar 17, 2015	M	3,898	$24.00	A	22,498	D
Common Stock	Mar 17, 2015	M	7,500	$24.00	A	29,998	D
Common Stock	Mar 17, 2015	F	393	$457.91	D	29,605	D
Common Stock	Mar 17, 2015	F	3,665	$457.91	D	25,940	D
Common Stock^F2	Mar 18, 2015	S	400	$462.84	D	25,540	D
Common Stock^F3	Mar 18, 2015	S	1,500	$463.60	D	24,040	D
Common Stock^F4	Mar 18, 2015	S	500	$464.44	D	23,540	D
Common Stock^F5	Mar 18, 2015	S	500	$465.42	D	23,040	D
Common Stock	Mar 18, 2015	S	100	$468.92	D	22,940	D
Common Stock	Mar 18, 2015	S	100	$469.68	D	22,840	D
Common Stock	Mar 18, 2015	S	142	$470.97	D	22,698	D
Common Stock	Mar 18, 2015	S	100	$471.24	D	22,598	D
Common Stock	Mar 18, 2015	S	100	$472.14	D	22,498	D
Common Stock	holding	—	—		—	407	I	By 401(k) Plan

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Incentive Stock Option (right to buy)^F6	$24.00	Mar 17, 2015	M	3,898	D	—	Mar 22, 2020	Common Stock	3,898	4,166	D
Non-Qualified Stock Option (right to buy)^F6	$24.00	Mar 17, 2015	M	7,500	D	—	Mar 22, 2020	Common Stock	7,500	14,168	D

Explanation of responses

F1Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
F2Represents volume-weighted average price of sales of 400 shares of Company stock on March 18, 2015 at prices ranging from $462.69 to $462.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 18, 2015 at each separate price.
F3Represents volume-weighted average price of sales of 1,500 shares of Company stock on March 18, 2015 at prices ranging from $463.24 to $463.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 18, 2015 at each separate price.
F4Represents volume-weighted average price of sales of 500 shares of Company stock on March 18, 2015 at prices ranging from $464.11 to $464.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 18, 2015 at each separate price.
F5Represents volume-weighted average price of sales of 500 shares of Company stock on March 18, 2015 at prices ranging from $465.02 to $465.75. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 18, 2015 at each separate price.
F6The stock option award (combined incentive stock option and non-qualified stock option) vests over five years, commencing one year after the date of grant. 12,500 options vest on the first anniversary, 25,000 options vest on the second anniversary, 25,000 options vest on the third anniversary, 25,000 options vest on the fourth anniversary, and 12,500 options vest on the fifth anniversary of the date of grant.